Immunohistochemical evaluation of androgen receptor expression in endometrial carcinoma and its clinicopathological significance - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of Androgen Receptor Expression in Endometrial Carcinoma via Immunohistochemistry and Its Clinical Implications

  • By

  • Alaa saad Abd elhamid Mohamed

  • Heba Ashraf Hosni

  • Maram Salaheldeen Mahmoud

  • Alzahraa Abdelmoktader Mohammed

  • September 26, 2026

Share

  • 1

    Endometrial carcinoma (EC) is the most commonly diagnosed gynecological malignancy in developed countries, with rising incidence and mortality rates.

  • 2

    Current EC classification includes four molecular groups: POLEmut, MMRd, p53abn, and NSMP, enhancing tumor behavior prediction and clinical management.

  • 3

    Androgen receptor (AR) activation may inhibit EC proliferation and migration, particularly in postmenopausal women through bioactive androgen production.

  • 4

    The study evaluates AR expression in EC tissue samples to assess its correlation with tumor differentiation, FIGO stage, and tumor grade.

  • 5

    Immunohistochemistry (IHC) was used to assess AR expression, with distinct nuclear staining indicating AR positivity in neoplastic glandular epithelial cells.

Original Source(s)

Immunohistochemical evaluation of androgen receptor expression in endometrial carcinoma and its clinicopathological significance

  • by Alaa saad Abd elhamid Mohamed, Heba Ashraf Hosni, Maram Salaheldeen Mahmoud, Alzahraa Abdelmoktader Mohammed

  • September 26, 2026

Related Content

Does active surveillance prior to radical prostatectomy increase the risk of adverse pathological findings or postoperative prostate cancer treatment?

Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis

Medicaid Expansion and Mortality Among Patients With Colorectal Cancer